HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

AbstractPURPOSE:
Patients with neurofibromatosis type 1 (NF1) develop malignant peripheral nerve sheath tumors (MPNST), which are often inoperable and do not respond well to current chemotherapies or radiation. The goal of this study was to use comprehensive gene expression analysis to identify novel therapeutic targets.
EXPERIMENTAL DESIGN:
Nerve Schwann cells and/or their precursors are the tumorigenic cell types in MPNST because of the loss of the NF1 gene, which encodes the RasGAP protein neurofibromin. Therefore, we created a transgenic mouse model, CNP-HRas12V, expressing constitutively active HRas in Schwann cells and defined a Ras-induced gene expression signature to drive a Bayesian factor regression model analysis of differentially expressed genes in mouse and human neurofibromas and MPNSTs. We tested functional significance of Aurora kinase overexpression in MPNST in vitro and in vivo using Aurora kinase short hairpin RNAs (shRNA) and compounds that inhibit Aurora kinase.
RESULTS:
We identified 2,000 genes with probability of linkage to nerve Ras signaling of which 339 were significantly differentially expressed in mouse and human NF1-related tumor samples relative to normal nerves, including Aurora kinase A (AURKA). AURKA was dramatically overexpressed and genomically amplified in MPNSTs but not neurofibromas. Aurora kinase shRNAs and Aurora kinase inhibitors blocked MPNST cell growth in vitro. Furthermore, an AURKA selective inhibitor, MLN8237, stabilized tumor volume and significantly increased survival of mice with MPNST xenografts.
CONCLUSION:
Integrative cross-species transcriptome analyses combined with preclinical testing has provided an effective method for identifying candidates for molecular-targeted therapeutics. Blocking Aurora kinases may be a viable treatment platform for MPNST.
AuthorsAmi V Patel, David Eaves, Walter J Jessen, Tilat A Rizvi, Jeffrey A Ecsedy, Mark G Qian, Bruce J Aronow, John P Perentesis, Eduard Serra, Timothy P Cripe, Shyra J Miller, Nancy Ratner
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 18 Issue 18 Pg. 5020-30 (Sep 15 2012) ISSN: 1078-0432 [Print] United States
PMID22811580 (Publication Type: Journal Article)
Copyright©2012 AACR.
Chemical References
  • Azepines
  • MLN 8237
  • Pyrimidines
  • AURKA protein, human
  • Aurka protein, mouse
  • Aurora Kinase A
  • Aurora Kinases
  • Protein-Serine-Threonine Kinases
  • Proto-Oncogene Proteins p21(ras)
Topics
  • Animals
  • Aurora Kinase A
  • Aurora Kinases
  • Azepines (pharmacology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cell Size (drug effects)
  • Cell Survival (drug effects, genetics)
  • Cluster Analysis
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Mice, Nude
  • Nerve Sheath Neoplasms (genetics, metabolism, therapy)
  • Protein-Serine-Threonine Kinases (antagonists & inhibitors, genetics, metabolism)
  • Proto-Oncogene Proteins p21(ras) (genetics, metabolism)
  • Pyrimidines (pharmacology)
  • Signal Transduction
  • Transcriptome
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: